Remdesivir (GS-5734) Is Efficacious in Cynomolgus Macaques Infected With Marburg Virus.
J Infect Dis
; 222(11): 1894-1901, 2020 11 09.
Article
in En
| MEDLINE
| ID: mdl-32479636
Marburg virus (MARV) is a filovirus with documented human case-fatality rates of up to 90%. Here, we evaluated the therapeutic efficacy of remdesivir (GS-5734) in nonhuman primates experimentally infected with MARV. Beginning 4 or 5 days post inoculation, cynomolgus macaques were treated once daily for 12 days with vehicle, 5 mg/kg remdesivir, or a 10-mg/kg loading dose followed by 5 mg/kg remdesivir. All vehicle-control animals died, whereas 83% of animals receiving a 10-mg/kg loading dose of remdesivir survived, as did 50% of animals receiving a 5-mg/kg remdesivir regimen. Remdesivir-treated animals exhibited improved clinical scores, lower plasma viral RNA, and improved markers of kidney function, liver function, and coagulopathy versus vehicle-control animals. The small molecule remdesivir showed therapeutic efficacy in this Marburg virus disease model with treatment initiation 5 days post inoculation, supporting further assessment of remdesivir for the treatment of Marburg virus disease in humans.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Marburgvirus
/
Marburg Virus Disease
/
Monkey Diseases
/
Antimetabolites
Type of study:
Prognostic_studies
Limits:
Animals
Language:
En
Journal:
J Infect Dis
Year:
2020
Document type:
Article
Affiliation country:
Estados Unidos
Country of publication:
Estados Unidos